Raptor Pharmaceutical Corp. (NASDAQ:RPTP) was down 1.5% during trading on Tuesday . The stock traded as low as $7.22 and last traded at $7.25, with a volume of 434,230 shares. The stock had previously closed at $7.36.

Several equities research analysts have recently commented on RPTP shares. Cowen and Company reiterated a “buy” rating and set a $8.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Friday. Zacks Investment Research raised shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a report on Thursday, August 11th. FBR & Co reissued a “hold” rating and set a $10.00 target price on shares of Raptor Pharmaceutical Corp. in a report on Tuesday. Citigroup Inc. cut shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and raised their target price for the stock from $6.00 to $8.00 in a report on Monday, August 8th. Finally, Wedbush reissued a “neutral” rating and set a $4.00 target price on shares of Raptor Pharmaceutical Corp. in a report on Friday, May 6th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Raptor Pharmaceutical Corp. presently has an average rating of “Hold” and a consensus price target of $7.79.

The firm’s 50-day moving average price is $6.29 and its 200-day moving average price is $5.15. The stock’s market capitalization is $622.73 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.02. The firm earned $32.05 million during the quarter, compared to analysts’ expectations of $28.52 million. The company’s revenue for the quarter was up 37.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.17) earnings per share. Equities analysts expect that Raptor Pharmaceutical Corp. will post ($0.91) EPS for the current fiscal year.

An institutional investor recently raised its position in Raptor Pharmaceutical Corp. stock. Schwab Charles Investment Management Inc. increased its stake in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 3.3% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 292,620 shares of the company’s stock after buying an additional 9,354 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.34% of Raptor Pharmaceutical Corp. worth $1,522,000 at the end of the most recent quarter.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.